Skip to main
CTSO
CTSO logo

CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents (CTSO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

CytoSorbents Corp demonstrated a robust financial performance with a reported revenue of $9.5 million, reflecting a 10% year-over-year growth and a gross margin exceeding 70%, attributed to improved geographic mix and manufacturing efficiencies. The company showcased significant advancements in distributor-driven revenue, with sales from global distribution partners growing 14.4% year-over-year, highlighting strong execution in international markets that supports the potential for future growth. Additionally, ongoing efforts to enhance the product pipeline, particularly DrugSorb-ATR, along with the anticipation of returning to growth in the German market by 2026, underscore a promising outlook for continued operational improvement and financial stability.

Bears say

CytoSorbents Corp has revised its revenue projections downward for both 2025 and 2026, reflecting a decline from $39.8 million to $38.2 million and from $46.3 million to $40.8 million, respectively. The company continues to experience stagnant commercial sales in Germany, which significantly impacts its overall revenue growth, given that this market is critical to its financial performance. Consequently, the adjusted price target for the stock has been reduced from $1.00 to $0.75 per share, further indicating concerns over the company's financial trajectory and performance outlook.

CytoSorbents (CTSO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytoSorbents (CTSO) Forecast

Analysts have given CytoSorbents (CTSO) a Buy based on their latest research and market trends.

According to 2 analysts, CytoSorbents (CTSO) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytoSorbents (CTSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.